Recent Updates
Recently added Catalysts

DMR-001

Phase 1

Myeloproliferative Neoplasms (MPNs) | Biologics | Oncology |Damora Therapeutics, Inc.|Trials Updated: Oct 27, 2026

DMR-001 development status

Highest phase Phase 1
Registered trials 1 across 1 sponsor since Sep 2026

DMR-001 target and mechanism

Molecular targetmutCALR
Target classProtein
ModalityBiologics

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

CONTROLLEDBiomarker
Total Trials1
Total Enrollment250

FDA Designations

No designations recorded

DMR-001 clinical trials

DMR-001 · 1 trial · 1 indication

Phase 1 1
NCT07849231A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative NeoplasmsMyeloproliferative Neoplasms (MPNs)
RECRUITING250 Analytics
PHASE1RECRUITING
A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms
Myeloproliferative Neoplasms (MPNs)Unlock trial analytics

Study Endpoints

Primary Endpoints

To evaluate the safety and tolerability of DMR-001 & determine the MTD, RDE(s), and/or recommended Phase 2 dose(s) in participants with CALR-mutant MPNs, when administered as monotherapy or in combination with ruxolitinib
Up to 672 days

Incidence and severity of AEs and SAEs, including DLTs and AEs resulting in dose modification (interruption, reduction, or discontinuation)

Secondary Endpoints

Evaluate preliminary clinical activity of DMR-001 as a monotherapy in participants with CALR-mutant ET
Up to 672 days
Evaluate preliminary clinical activity of DMR-001 as a monotherapy or in combination with ruxolitinib in participants with CALR-mutant MF
Up to 672 days
Pharmacokinetics parameter: Cmax of DMR-001 when administered as monotherapy or in combination with ruxolitinib
Up to 672 days
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelSEQUENTIAL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Part 1: DMR-001 monotherapy dose escalation phase.EXPERIMENTALDMR-001 will be administered starting once every 4 weeks as a subcutaneous injection at the protocol defined starting dose and dosing schedule to identify the maximum tolerated dose and/or recommended dose(s) for expansion.
Part 2: DMR-001 monotherapy dose expansion phase.EXPERIMENTALDMR-001 will be administered starting once every 4 weeks as a subcutaneous injection at the determined recommended dose(s) for expansion based on Part 1.
Part 3: DMR-001 and ruxolitinib combination dose escalation followed by dose expansion.EXPERIMENTALDMR-001 will be administered starting once every 4 weeks as a subcutaneous injection at the determined dose and regimen, but in combination with an oral tablet of ruxolitinib, a standard of care drug approved therapy for the treatment of MF.

Interventions

NameTypeDescription
DMR-001DRUGDMR-001 will be administered at protocol defined dose at a frequency of every 4 weeks.
RuxolitinibDRUGRuxolitinib will be administered according to Prescribing Information/SmPC.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites36

Inclusion Criteria: * Signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and the protocol. * Diagnosis/confirmation of ET or MF as defined in the protocol. * Documented CALR exon-9 mutation. * Willingness to undergo bone marrow biopsy and asp...

Countries:United StatesAustralia
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWOct 27, 2026NCT07849231lastUpdatePostDate: changed
LOWOct 27, 2026NCT07849231lastUpdatePostDate: changed
LOWOct 7, 2026NCT07849231lastUpdatePostDate: changed
LOWOct 7, 2026NCT07849231lastUpdatePostDate: changed
LOWSep 30, 2026NCT07849231NEW_TRIAL: changed
LOWSep 30, 2026NCT07849231NEW_TRIAL: changed

Frequently asked questions about DMR-001

What is DMR-001?

DMR-001 is an investigational small molecule developed by Damora Therapeutics, Inc. for myeloproliferative neoplasms (MPNs). It is designed to target mutCALR, a mutant form of the calreticulin protein, and is being studied in biomarker-selected patients whose disease carries that mutation. DMR-001 is in Phase 1 clinical development.

What does DMR-001 target?

DMR-001 targets mutCALR, the mutant form of the calreticulin protein found in a subset of myeloproliferative neoplasms. By binding this mutant protein target, DMR-001 is intended to act on the disease-driving abnormality specific to CALR-mutant MPN patients, which is why the clinical program enrolls only biomarker-selected participants.

Who is developing DMR-001?

DMR-001 is being developed by Damora Therapeutics, Inc., a biopharmaceutical company whose common stock trades under the ticker DMRA. Damora is the sponsor of the Phase 1 study evaluating DMR-001 in CALR-mutant myeloproliferative neoplasms in the United States and Australia.

What phase is DMR-001 in?

DMR-001 is in Phase 1 clinical development. It is an investigational agent and has not been approved by the FDA for any indication. The Phase 1 program consists of one active, recruiting study in CALR-mutant myeloproliferative neoplasms, with no completed trials reported to date.

What clinical trial is DMR-001 in?

DMR-001 is being evaluated in trial NCT07849231, titled A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms. The Phase 1 study is currently recruiting, plans to enroll 250 participants aged 18 years and older of all sexes, and is running in the United States and Australia.

Is the DMR-001 trial randomized and controlled?

The DMR-001 Phase 1 study NCT07849231 is a controlled trial but is not randomized and is not double-blind. It enrolls only biomarker-selected participants with CALR-mutant myeloproliferative neoplasms, does not include healthy volunteers, and is recruiting at sites in the United States and Australia with a planned enrollment of 250.